Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1569–1575. doi: 10.1038/bjc.1996.296

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

J H Schellens 1, J Ma 1, A S Planting 1, M E van der Burg 1, E van Meerten 1, M de Boer-Dennert 1, P I Schmitz 1, G Stoter 1, J Verweij 1
PMCID: PMC2074557  PMID: 8664132

Abstract

The study was designed to investigate possible relationships between tumour response and exposure to cisplatin (area under the curve of unbound cisplatin in plasma, AUC) and DNA-adduct formation in leucocytes (WBC) in patients with solid tumours. Patients were treated with six weekly courses of cisplatin at a dose of 70 or 80 mg m-2. The AUC was determined during the first course and DNA-adduct levels in WBC during all courses at baseline, 1 h (A(max)) and 15 h after a 3 h infusion of cisplatin. The area under the DNA-adduct-time curve (AUA) was calculated. The tumour response was determined after six courses. Forty-five evaluable patients received 237 courses of cisplatin. Sixteen patients with head and neck cancer received a dose of 80 mg m-2 and 29 with various other tumour types received 70 mg m-2 plus daily 50 mg oral etoposide. There were 20 responders (partial and complete) and 25 non-responders (stable and progressive disease). The AUC was highly variable (mean +/- s.d. = 2.48 +/- 0.51 micrograms h-1 ml-1; range 1.10-3.82) and was closely correlated with the AUA (r = 0.78, P < 0.0001) and A(max) (r = 0.73, P < 0.0001). The AUC, AUA and A(max) were significantly higher in responders than in non-responders in the total population (P < 0.0001) and in the two subgroups treated at 70 or 80 mg m-2. In logistic regression analysis AUC, AUA and A(max) were important predictors of response. The magnitude of exposure to cisplatin is, through DNA-adduct formation, the major determinant of the response rate in this population. Hence, individualised dosing of cisplatin using AUC or DNA-adducts should lead to increased response rates.

Full text

PDF
1569

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Garcia D., Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol. 1991 Feb;18(1 Suppl 3):11–24. [PubMed] [Google Scholar]
  2. Bajorin D. F., Sarosdy M. F., Pfister D. G., Mazumdar M., Motzer R. J., Scher H. I., Geller N. L., Fair W. R., Herr H., Sogani P. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993 Apr;11(4):598–606. doi: 10.1200/JCO.1993.11.4.598. [DOI] [PubMed] [Google Scholar]
  3. Blommaert F. A., Michael C., Terheggen P. M., Muggia F. M., Kortes V., Schornagel J. H., Hart A. A., den Engelse L. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res. 1993 Dec 1;53(23):5669–5675. [PubMed] [Google Scholar]
  4. Bruckner H. W., Wallach R., Cohen C. J., Deppe G., Kabakow B., Ratner L., Holland J. F. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol. 1981 Aug;12(1):64–67. doi: 10.1016/0090-8258(81)90095-0. [DOI] [PubMed] [Google Scholar]
  5. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  6. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  7. Cavaletti G., Marzorati L., Bogliun G., Colombo N., Marzola M., Pittelli M. R., Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992 Jan 1;69(1):203–207. doi: 10.1002/1097-0142(19920101)69:1<203::aid-cncr2820690133>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  8. Childs W. J., Nicholls E. J., Horwich A. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol. 1992 Apr;3(4):291–296. doi: 10.1093/oxfordjournals.annonc.a058182. [DOI] [PubMed] [Google Scholar]
  9. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry. 1986 Jul 1;25(13):3912–3915. doi: 10.1021/bi00361a026. [DOI] [PubMed] [Google Scholar]
  10. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry. 1988 Jun 28;27(13):4730–4734. doi: 10.1021/bi00413a022. [DOI] [PubMed] [Google Scholar]
  11. Egorin M. J., Van Echo D. A., Olman E. A., Whitacre M. Y., Forrest A., Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985 Dec;45(12 Pt 1):6502–6506. [PubMed] [Google Scholar]
  12. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  13. Fichtinger-Schepman A. M., van Oosterom A. T., Lohman P. H., Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 1987 Jun 1;47(11):3000–3004. [PubMed] [Google Scholar]
  14. Gill I., Muggia F. M., Terheggen P. M., Michael C., Parker R. J., Kortes V., Grunberg S., Christian M. C., Reed E., den Engelse L. Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts. Ann Oncol. 1991 Feb;2(2):115–121. doi: 10.1093/oxfordjournals.annonc.a057872. [DOI] [PubMed] [Google Scholar]
  15. Glover D., Glick J. H., Weiler C., Fox K., Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987 Apr;5(4):574–578. doi: 10.1200/JCO.1987.5.4.574. [DOI] [PubMed] [Google Scholar]
  16. Goldberg J. M., Lindblom U. Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry. 1979 Sep;42(9):793–803. doi: 10.1136/jnnp.42.9.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hainsworth J. D., Greco F. A. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993 Jul 22;329(4):257–263. doi: 10.1056/NEJM199307223290407. [DOI] [PubMed] [Google Scholar]
  18. Hansen H. H. Management of small-cell cancer of the lung. Lancet. 1992 Apr 4;339(8797):846–849. doi: 10.1016/0140-6736(92)90287-d. [DOI] [PubMed] [Google Scholar]
  19. Hengstler J. G., Fuchs J., Oesch F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res. 1992 Oct 15;52(20):5622–5626. [PubMed] [Google Scholar]
  20. Himmelstein K. J., Patton T. F., Belt R. J., Taylor S., Repta A. J., Sternson L. A. Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther. 1981 May;29(5):658–664. doi: 10.1038/clpt.1981.91. [DOI] [PubMed] [Google Scholar]
  21. Jodrell D. I., Egorin M. J., Canetta R. M., Langenberg P., Goldbloom E. P., Burroughs J. N., Goodlow J. L., Tan S., Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992 Apr;10(4):520–528. doi: 10.1200/JCO.1992.10.4.520. [DOI] [PubMed] [Google Scholar]
  22. Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C., Cruickshank D. J., Atkinson R. J., Soukop M., Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329–333. doi: 10.1016/0140-6736(92)91404-v. [DOI] [PubMed] [Google Scholar]
  23. Krarup-Hansen A., Hansen H. H. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol. 1991;28(5):319–330. doi: 10.1007/BF00685684. [DOI] [PubMed] [Google Scholar]
  24. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  25. Levin L., Simon R., Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst. 1993 Nov 3;85(21):1732–1742. doi: 10.1093/jnci/85.21.1732. [DOI] [PubMed] [Google Scholar]
  26. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  27. Logothetis C. J., Amato R. J. Dose intensity in germ cell tumors: lessons learned? J Natl Cancer Inst. 1992 Nov 18;84(22):1686–1687. doi: 10.1093/jnci/84.22.1686. [DOI] [PubMed] [Google Scholar]
  28. Ma J., Verweij J., Planting A. S., de Boer-Dennert M., van Ingen H. E., van der Burg M. E., Stoter G., Schellens J. H. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer. 1995 Mar;71(3):512–517. doi: 10.1038/bjc.1995.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Markman M. The role of platinum dose intensity in the management of ovarian cancer. J Cancer Res Clin Oncol. 1993;119(9):511–512. doi: 10.1007/BF01686459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Motzer R. J., Bosl G. J., Geller N. L., Penenberg D., Yagoda A., Golbey R., Whitmore W. F., Jr, Fair W. R., Sogani P., Herr H. Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med. 1988 Apr;108(4):513–518. doi: 10.7326/0003-4819-108-4-513. [DOI] [PubMed] [Google Scholar]
  31. Motzer R. J., Reed E., Perera F., Tang D., Shamkhani H., Poirier M. C., Tsai W. Y., Parker R. J., Bosl G. J. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer. 1994 Jun 1;73(11):2843–2852. doi: 10.1002/1097-0142(19940601)73:11<2843::aid-cncr2820731130>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  32. Ozols R. F., Ihde D. C., Linehan W. M., Jacob J., Ostchega Y., Young R. C. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988 Jun;6(6):1031–1040. doi: 10.1200/JCO.1988.6.6.1031. [DOI] [PubMed] [Google Scholar]
  33. Paccagnella A., Orlando A., Marchiori C., Zorat P. L., Cavaniglia G., Sileni V. C., Jirillo A., Tomio L., Fila G., Fede A. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994 Feb 16;86(4):265–272. doi: 10.1093/jnci/86.4.265. [DOI] [PubMed] [Google Scholar]
  34. Parker R. J., Gill I., Tarone R., Vionnet J. A., Grunberg S., Muggia F. M., Reed E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis. 1991 Jul;12(7):1253–1258. doi: 10.1093/carcin/12.7.1253. [DOI] [PubMed] [Google Scholar]
  35. Planting A. S., Schellens J. H., Goey S. H., van der Burg M. E., de Boer-Dennert M., Stoter G., Verweij J. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol. 1994 Apr;5(4):373–374. doi: 10.1093/oxfordjournals.annonc.a058846. [DOI] [PubMed] [Google Scholar]
  36. Planting A. S., van der Burg M. E., de Boer-Dennert M., Stoter G., Verweij J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer. 1993 Oct;68(4):789–792. doi: 10.1038/bjc.1993.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Poirier M. C., Reed E., Litterst C. L., Katz D., Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 1992 Jan 1;52(1):149–153. [PubMed] [Google Scholar]
  38. Poirier M. C., Reed E., Shamkhani H., Tarone R. E., Gupta-Burt S. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect. 1993 Mar;99:149–154. doi: 10.1289/ehp.9399149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Reece P. A., Stafford I., Abbott R. L., Anderson C., Denham J., Freeman S., Morris R. G., Gill P. G., Olweny C. L. Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol. 1989 Feb;7(2):270–275. doi: 10.1200/JCO.1989.7.2.270. [DOI] [PubMed] [Google Scholar]
  40. Reece P. A., Stafford I., Russell J., Khan M., Gill P. G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987 Feb;5(2):304–309. doi: 10.1200/JCO.1987.5.2.304. [DOI] [PubMed] [Google Scholar]
  41. Reed E., Ostchega Y., Steinberg S. M., Yuspa S. H., Young R. C., Ozols R. F., Poirier M. C. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res. 1990 Apr 15;50(8):2256–2260. [PubMed] [Google Scholar]
  42. Reed E., Ozols R. F., Tarone R., Yuspa S. H., Poirier M. C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024–5028. doi: 10.1073/pnas.84.14.5024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Reed E., Ozols R. F., Tarone R., Yuspa S. H., Poirier M. C. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis. 1988 Oct;9(10):1909–1911. doi: 10.1093/carcin/9.10.1909. [DOI] [PubMed] [Google Scholar]
  44. Reed E., Parker R. J., Gill I., Bicher A., Dabholkar M., Vionnet J. A., Bostick-Bruton F., Tarone R., Muggia F. M. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res. 1993 Aug 15;53(16):3694–3699. [PubMed] [Google Scholar]
  45. Reed E., Yuspa S. H., Zwelling L. A., Ozols R. F., Poirier M. C. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest. 1986 Feb;77(2):545–550. doi: 10.1172/JCI112335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Roelofs R. I., Hrushesky W., Rogin J., Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul;34(7):934–938. doi: 10.1212/wnl.34.7.934. [DOI] [PubMed] [Google Scholar]
  47. Roth J. A., Fossella F., Komaki R., Ryan M. B., Putnam J. B., Jr, Lee J. S., Dhingra H., De Caro L., Chasen M., McGavran M. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 4;86(9):673–680. doi: 10.1093/jnci/86.9.673. [DOI] [PubMed] [Google Scholar]
  48. Samson M. K., Rivkin S. E., Jones S. E., Costanzi J. J., LoBuglio A. F., Stephens R. L., Gehan E. A., Cummings G. D. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer. 1984 Mar 1;53(5):1029–1035. doi: 10.1002/1097-0142(19840301)53:5<1029::aid-cncr2820530503>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  49. Sheiner L. B., Beal S. L. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985 Apr;13(2):185–201. doi: 10.1007/BF01059398. [DOI] [PubMed] [Google Scholar]
  50. Siegal T., Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990 Sep 15;66(6):1117–1123. doi: 10.1002/1097-0142(19900915)66:6<1117::aid-cncr2820660607>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  51. Slotman G. J., Doolittle C. H., Glicksman A. S. Preoperative combined chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Five-year results with impressive complete response rates and high survival. Cancer. 1992 Jun 1;69(11):2736–2743. doi: 10.1002/1097-0142(19920601)69:11<2736::aid-cncr2820691118>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  52. Stoter G., Splinter T. A., Child J. A., Fosså S. D., Denis L., van Oosterom A. T., de Pauw M., Sylvester R. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol. 1987 Apr;137(4):663–667. doi: 10.1016/s0022-5347(17)44168-1. [DOI] [PubMed] [Google Scholar]
  53. van der Hoop R. G., Vecht C. J., van der Burg M. E., Elderson A., Boogerd W., Heimans J. J., Vries E. P., van Houwelingen J. C., Jennekens F. G., Gispen W. H. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990 Jan 11;322(2):89–94. doi: 10.1056/NEJM199001113220204. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES